Emergency EEG maker Ceribell raises $35M in series B round

The system's headband includes a “brain stethoscope” feature that converts EEG signals to sound. (Image: Whipsaw)

Ceribell raised $35 million to fund commercialization of its rapid response EEG system, which can quickly diagnose patients suspected of having nonconvulsive seizures with no visual symptoms, for use in neurological intensive care units and emergency rooms.

The Mountain View, California-based company’s platform, which received 510(k) clearance from the FDA in 2017, is designed to diagnose patients within six minutes, compared to typical EEGs that may take hours or days, according to Ceribell.

The system consists of a disposable headband and cloud-based mobile recording device, allowing a specialist to review the patient’s EEG remotely. It also includes a “brain stethoscope” feature that converts EEG signals to sound.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The series B round was led by Optimas Capital Partners Fund and The Rise Fund, which is managed by TPG Growth, plus funding from the pharma company UCB and medtech developer LivaNova.

“Ceribell’s unique approach combining user-centric design, AI data analytics and digital health has the potential to revolutionize how clinicians monitor for seizures and minimize the time from seizure onset to treatment,” said Heath Lukatch, partner at TPG.

“This platform can not only have a significant positive impact on the health and treatment of patients in the United States, but also more broadly across the world where EEG and trained neurologists are not available,” Lukatch added.

Suggested Articles

The FDA disclosed over 60 safety reports related to intra-aortic balloon pumps manufactured by Maquet and Datascope, following a recall this summer.

Truvian Sciences raised $27.1 million to fuel the development of its benchtop blood tester, bringing the company’s total funding to $46.3 million.

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.